These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 16918377)

  • 1. The role of high-density lipoprotein cholesterol in the prevention and possible treatment of cardiovascular diseases.
    Choi BG; Vilahur G; Yadegar D; Viles-Gonzalez JF; Badimon JJ
    Curr Mol Med; 2006 Aug; 6(5):571-87. PubMed ID: 16918377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of high-density lipoprotein cholesterol in atherothrombosis.
    Choi BG; Vilahur G; Viles-Gonzalez JF; Badimon JJ
    Mt Sinai J Med; 2006 Jul; 73(4):690-701. PubMed ID: 16878275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Postgrad Med J; 2008 Nov; 84(997):590-8. PubMed ID: 19103817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C.
    Chapman MJ; Assmann G; Fruchart JC; Shepherd J; Sirtori C;
    Curr Med Res Opin; 2004 Aug; 20(8):1253-68. PubMed ID: 15324528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of fibric acid derivatives in the management of risk factors for coronary heart disease.
    Després JP; Lemieux I; Robins SJ
    Drugs; 2004; 64(19):2177-98. PubMed ID: 15456334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.
    Jacobson TA
    Int J Clin Pract; 2011 Jan; 65(1):82-101. PubMed ID: 21105969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment.
    Hersberger M; von Eckardstein A
    Drugs; 2003; 63(18):1907-45. PubMed ID: 12930163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal therapy of low levels of high density lipoprotein-cholesterol.
    Kashyap ML; Tavintharan S; Kamanna VS
    Am J Cardiovasc Drugs; 2003; 3(1):53-65. PubMed ID: 14727946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reducing cardiovascular risk by targeting high-density lipoprotein cholesterol.
    Toth PP
    Curr Atheroscler Rep; 2007 Jan; 9(1):81-8. PubMed ID: 17169252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HDL-cholesterol: is it really good? Differences between apoA-I and HDL.
    Santos-Gallego CG; Ibanez B; Badimon JJ
    Biochem Pharmacol; 2008 Aug; 76(4):443-52. PubMed ID: 18547543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current, new and future treatments in dyslipidaemia and atherosclerosis.
    Chong PH; Bachenheimer BS
    Drugs; 2000 Jul; 60(1):55-93. PubMed ID: 10929930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancing cardiovascular disease risk reduction: raising high-density lipoprotein levels.
    Hausenloy DJ; Yellon DM
    Curr Opin Cardiol; 2009 Sep; 24(5):473-82. PubMed ID: 19574922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HDL-C: role as a risk modifier.
    Barter P
    Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Have we forgotten the pivotal role of high-density lipoprotein cholesterol in atherosclerosis prevention?
    Wierzbicki AS
    Curr Med Res Opin; 2005 Feb; 21(2):299-306. PubMed ID: 15802001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current status and future directions in lipid management: emphasizing low-density lipoproteins, high-density lipoproteins, and triglycerides as targets for therapy.
    Lin Y; Mousa SS; Elshourbagy N; Mousa SA
    Vasc Health Risk Manag; 2010 Mar; 6():73-85. PubMed ID: 20234782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treating high density lipoprotein cholesterol (HDL-C): quantity versus quality.
    Pirillo A; Norata GD; Catapano AL
    Curr Pharm Des; 2013; 19(21):3841-57. PubMed ID: 23286430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.